FDAnews
www.fdanews.com/articles/192598-orchestra-biomed-receives-ce-mark-for-implantable-hypertension-treatment

Orchestra BioMed Receives CE Mark for Implantable Hypertension Treatment

September 4, 2019

Orchestra BioMed has gained the CE Mark for its Moderato implantable pulse generator for treating hypertension while also serving as a pacemaker.

The system uses an implantable cardiac stimulation-based treatment for hypertension that immediately lowers the patient’s blood pressure while modulating the autonomic nervous system.

The principal investigator for the Moderato studies, Karl-Heinz Kuck, said the device has potential to be “a primary treatment” for hypertension.

View today's stories